Europe’s Only End-To-End Clinical Biomarker & Companion Diagnostics Summit
Full speakers and session for the 12th Clinical Biomarkers & CDx Summit Europe agenda will be released in December, but in the meantime you can take a sneak peak at the agenda here.
Here’s what to expect in April:
Reviewing the Competitive Precision Medicine Landscape
Explore the successes and challenges encountered throughout end-to-end companion diagnostic programs in oncology & hear future directions for precision medicine progress in general medicine
Deep Dive into the Changing Regulatory Environment in Europe & Beyond!
With incoming IVDR creating complexities for precision drug development, Brexit regulatory impacts, significant considerations for entry into global markets – Develop biomarker-based medicines enabling defined clinical endpoints which create a clear path forward for regulatory approval
Hear Latest Updates on Fluid-Based Biomarker Detection
Hear how you can harness non-invasive testing technology to identify new drug targets, measure resistance, shorten clinical timeframes and see improved patient stratification, enrolment & study retention through quicker, cheaper and patient centric means
Get Strategic Insight From Biomarker Development Programs
From biomarker discovery through to translation and clinical phases, there is practical insight you can gain to identify patient populations for your drug-development program
Develop Competitive Go-to-Market Strategies in a Complex Reimbursement Landscape
Hear how Drug-Dx program planning can maximise your market share and access through clinical utility demonstration with reimbursement organizations across the continent